65,437 trials
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Surgery of Right Upper Extremity
Primary: Number of Subjects With Hemidiaphragmatic Paresis at Various Volumes of Local Anesthetic 15 Minutes After Supraclavicular Block — 1; 1; 1; 2 Participants
Preeclampsia
Primary: Maternal Serum Magnesium Level at 4 Hours After Administration — 3.53; 4.41 mg/dL
Type 2 Diabetes Mellitus
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
Multiple Myeloma (MM)
Primary: Safety Profile of Acalabrutinib With and Without Dexamethasone — 13; 14; 7; 7 Participants
Insulin Hypoglycemia · Type 1 Diabetes Mellitus · Severe Hypoglycemia
Primary: Severe Hypoglycemia Rescue — 127; 123 Participants
Advanced Angiosarcoma
Primary: Progression Free Survival of Patients With Unresectable Angiosarcoma — 4.2; 4.3; 3.5; 2.9 months
Carcinoma, Non Small Cell Lung
Primary: Progression-free Survival in Months — 2.8; 1.6 months
Cocaine Use Disorder
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) - Heart Rate — 7.8; 4.96 beats per minute
Neurogenic Detrusor Overactivity
Primary: Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24 — 72.09; 113.21 mL — p=<0.001
Accidental Falls
Primary: Enrollment — 342; 142; 23; 177 participants
Heart Failure · Sleep Disordered Breathing
Primary: All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure — 360; 335 Participants
Arthropathy of Knee Joint
Primary: Number of Patients With Total Knee Replacement Performed Without Opioids Through 12 Weeks Postoperative — 73 Participants
Hypertension
Primary: Frequency of Patients With Any Suspected Adverse Drug Reactions — 32 Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-906 — 19.76; 17.24 nanogram per milliliter (ng/mL) — p=0.3011